Blincyto Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The blincyto market size has grown strongly in recent years. It will grow from $0.81 million in 2025 to $0.86 million in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to limitations of conventional chemotherapy, rising incidence of blood cancers, advancements in monoclonal antibody research, unmet needs in relapsed leukemia, hospital-based cancer treatment models.

The blincyto market size is expected to see strong growth in the next few years. It will grow to $1.08 million in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to growth in precision medicine adoption, increasing approvals for immunotherapies, expansion of specialty oncology centers, rising clinical trial activity, improved patient survival outcomes. Major trends in the forecast period include rising adoption of immuno-oncology therapies, growing use of bi-specific antibody treatments, expansion of targeted cancer immunotherapy, increased focus on minimal residual disease treatment, shift toward precision oncology approaches.

The rising incidence of leukemia is expected to drive the growth of the Blincyto market going forward. Leukemia is a cancer that originates in blood-forming tissues such as the bone marrow, resulting in the excessive production of abnormal white blood cells that disrupt normal blood cell function. The increase in leukemia cases is linked to factors including aging populations, environmental exposure, genetic susceptibility, and improvements in diagnostic technologies. Blincyto is used in leukemia treatment as a bispecific T-cell engager that enables the immune system to identify and eliminate leukemia cells, particularly in patients with acute lymphoblastic leukemia (ALL). For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, approximately 62,770 new leukemia cases were expected in the United States in 2024, compared with 59,610 cases in 2023. Therefore, the increasing incidence of leukemia is driving the growth of the Blincyto market.

Rising healthcare spending is expected to further propel the growth of the Blincyto market going forward. Healthcare spending refers to total expenditures on healthcare services and products, including personal medical care, public health initiatives, and administrative services. Healthcare expenditure is increasing due to factors such as population growth, aging demographics, higher service costs, a growing burden of chronic diseases, and advancements in medical technology. Increased healthcare spending improves access to advanced cancer therapies such as Blincyto, supporting wider adoption and better patient outcomes. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, healthcare expenditure in the UK reached approximately $363 billion in 2023, reflecting a nominal increase of 5.6% from the previous year, significantly higher than the 0.9% growth recorded in 2022. Therefore, rising healthcare spending is driving the Blincyto market.

Major companies operating in the Blincyto market are concentrating on the development of innovative therapies, including immuno-oncology treatments, to precisely target and destroy cancer cells. Immuno-oncology therapy is a cancer treatment approach that harnesses the body’s immune system to recognize, attack, and eliminate cancer cells. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, received approval from the US Food and Drug Administration (FDA) for BLINCYTO (blinatumomab) for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase in both adult and pediatric patients aged one month and older, regardless of measurable residual disease (MRD) status. BLINCYTO functions as a bispecific T-cell engager (BiTE), simultaneously binding to CD19 on B-cell malignancies and CD3 on T-cells, thereby directing T-cells to attack and destroy cancer cells.

Major companies operating in the blincyto market are Amgen Inc.

North America was the largest region in the Blincyto market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blincyto market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blincyto market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the blincyto market by increasing costs for imported biologic raw materials, infusion delivery systems, and specialized manufacturing inputs. These cost pressures have influenced treatment affordability in oncology centers, particularly in regions dependent on imported biologics. Hospital pharmacy and specialty oncology segments in asia-pacific and latin america are among the most affected. Conversely, tariffs have encouraged regional biologics production, investment in advanced manufacturing, and long-term supply chain resilience for cancer immunotherapies.

The blincyto market research report is one of a series of new reports that provides blincyto market statistics, including blincyto industry global market size, regional shares, competitors with a blincyto market share, detailed blincyto market segments, market trends and opportunities, and any further data you may need to thrive in the blincyto industry. This blincyto market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blincyto (blinatumomab) is a prescription drug used to treat certain types of blood cancers. It is a bispecific T-cell engager (BiTE) antibody construct that functions by connecting cancerous B cells with T cells, a type of immune cell. Blincyto works by harnessing the body’s immune system to recognize and eliminate malignant B cells.

The types of Blincyto include prefilled and non-prefilled formulations. Prefilled Blincyto refers to a ready-to-use form in which the medication is supplied in preassembled syringes or vials, making preparation and administration more convenient. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies for the treatment of acute lymphoblastic leukemia and other hematological disorders. The medication is used in hospitals, clinics, and research institutions.

The blincyto market consists of sales of oncology medications, biosimilars, immunotherapy drugs, anti-inflammatory medications and hematology medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.